Research Article | Volume: 16, Issue: 10, October, 2026

Chromatographic Profiling of Encorafenib Impurities Using HPLC and LC-MS/MS Structural Characterization and In Silico Toxicity Evaluation of Degradation Products

Katari Ravi Babu,  Gowri Sankar Reddipalli   

Open Access   

Published:  Sep 17, 2026

DOI: 10.1177/22313354261472049
Abstract

This study systematically evaluated the impurities of Encorafenib along with structural elucidation, and in silico toxicological potential of its degradation products (DPs). The HPLC resolution of Encorafenib and its impurities was achieved on a Waters Symmetry C18 column using an isocratic mobile phase of methanol and 0.1 M ammonium acetate (pH 4.1, 60:40 v/v) at a flow rate of 0.85 mL/min with detection at 231 nm. The method effectively resolves Encorafenib and its three known impurities (Rs > 2) with acceptable ICH validation criteria such as linearity (r² > 0.999), sensitivity (LOD: 0.075 µg/mL), precision (RSD < 2%), robustness, and specificity. The base hydrolysis induces 16.31% degradation of Encorafenib with the formation of three new DPs, whereas acid stress produces 8.28% degradation. The LC-MS/MS analysis with fragmentation pattern was utilized for structural elucidation of major DPs. The in silico toxicity assessment proves that acid DP 2 and base DPs 3 and 4 display moderate toxicity (Class 4; LD50: 1000–1300 mg/kg), whereas base DP 1 shows high toxicity (Class 3; LD50: 155 mg/kg). The ADMET prediction using the pkCSM tool indicates favorable absorption characteristics and absence of predicted mutagenicity. Hepatotoxicity was predicted for all DPs; DP3 shows hERG II inhibition, and DP4 displays a broad toxicity profile. The developed method and comprehensive characterization of DPs provide a solid foundation for routine analysis and stability studies of Encorafenib.


Keyword:     Encorafenib impurity analysis forced degradation characterization of degradation products in silico toxicity


Citation:

Babu KR, Reddipalli GS. Chromatographic Profiling of Encorafenib Impurities Using HPLC and LC-MS/MS Structural Characterization and In Silico Toxicity Evaluation of Degradation Products. J Appl Pharm Sci. 2026;16(10):1081-1093. https://doi.org/10.1177/22313354261472049

Copyright: © The Author(s). This open-access article is distributed under the Creative Commons Attribution-NonCommercial 4.0 International License, which permits non-commercial use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given, a link to the license is included, and any changes are indicated.

HTML Full Text

Reference

Article Metrics
42 Views 25 Downloads 67 Total

Year

Month

Related Search

By author names